Contributions
Abstract: PB2358
Type: Publication Only
Background
The immature platelet fraction (IPF) is a predictive factor in increased platelet production associated with platelet immunomediated consumption or platelet destruction which results from the suppression of bone marrow production.
Aims
We evaluated the value of immature platelet fraction (IPF) in distinguish between immune thrombocytopenic purpura (ITP) and aplastic anemia (AA). Additionally, in order to evaluate its potential usefulness as a diagnostic marker, we detected IPF in other hematologic diseases including myelodysplastic syndrome (MDS) and myeloproliferative neoplasms such as polycythemia vera (PV), essential thrombocythemia (ET) and chronic myelogenous leukemia (CML).
Methods
10 patients with ITP were compared with 12 patients with AA, 8 patients with MDS, 6 patients with ET, 4 patients with PV, 8 patients with CML and 80 age- and sex- matched healthy controls. Complete blood count tests including IPF, platelet distribution width (PDW), mean platelet volume (MPV), platelet large cell ratio (P-LCR), plateletcrit (PCT) were performed using Sysmex XN-2000 (Sysmex, Kobe, Japan).
Results
Mean IPF was 16.1% in patients with ITP, 4.0% in patients with AA, 11.2% in patients with MDS, 2.5% in patients with ET, 3.2% in patients with PV, 7.2% in patients with CML and 3.1% in the control group (p<0.05). ITP patients showed high IPF, PDW, MPV, and P-LCR compared with other groups, while PCT was lower in ITP patients than other groups.
Conclusion
We found highly elevated IPF in disorders related to increased platelet production, particularly associated with platelet destruction such as ITP. Especially in thrombocytopenic patients, IPF showed significant differences between ITP and AA. MDS patients resulting from the decreased platelet production associated with bone marrow suppression showed slightly increased IPF rather than healthy controls. ET and PV showed normal ITP comparing with healthy controls. Interestingly, CML with fibrosis 2 cases revealed significantly higher IPF (mean:15.1%) than CML without fibrosis 6 cases (mean:4.6%). Besides ITP, we found elevated IPF in MDS and CML. The IPF is highly recommended to evaluate the thrombopoietic status of bone marrow in thrombocytopenia patients.
Session topic: 33. Platelets disorders
Keyword(s): Diagnosis, Hematological malignancy, Immune thrombocytopenia (ITP), Platelet
Abstract: PB2358
Type: Publication Only
Background
The immature platelet fraction (IPF) is a predictive factor in increased platelet production associated with platelet immunomediated consumption or platelet destruction which results from the suppression of bone marrow production.
Aims
We evaluated the value of immature platelet fraction (IPF) in distinguish between immune thrombocytopenic purpura (ITP) and aplastic anemia (AA). Additionally, in order to evaluate its potential usefulness as a diagnostic marker, we detected IPF in other hematologic diseases including myelodysplastic syndrome (MDS) and myeloproliferative neoplasms such as polycythemia vera (PV), essential thrombocythemia (ET) and chronic myelogenous leukemia (CML).
Methods
10 patients with ITP were compared with 12 patients with AA, 8 patients with MDS, 6 patients with ET, 4 patients with PV, 8 patients with CML and 80 age- and sex- matched healthy controls. Complete blood count tests including IPF, platelet distribution width (PDW), mean platelet volume (MPV), platelet large cell ratio (P-LCR), plateletcrit (PCT) were performed using Sysmex XN-2000 (Sysmex, Kobe, Japan).
Results
Mean IPF was 16.1% in patients with ITP, 4.0% in patients with AA, 11.2% in patients with MDS, 2.5% in patients with ET, 3.2% in patients with PV, 7.2% in patients with CML and 3.1% in the control group (p<0.05). ITP patients showed high IPF, PDW, MPV, and P-LCR compared with other groups, while PCT was lower in ITP patients than other groups.
Conclusion
We found highly elevated IPF in disorders related to increased platelet production, particularly associated with platelet destruction such as ITP. Especially in thrombocytopenic patients, IPF showed significant differences between ITP and AA. MDS patients resulting from the decreased platelet production associated with bone marrow suppression showed slightly increased IPF rather than healthy controls. ET and PV showed normal ITP comparing with healthy controls. Interestingly, CML with fibrosis 2 cases revealed significantly higher IPF (mean:15.1%) than CML without fibrosis 6 cases (mean:4.6%). Besides ITP, we found elevated IPF in MDS and CML. The IPF is highly recommended to evaluate the thrombopoietic status of bone marrow in thrombocytopenia patients.
Session topic: 33. Platelets disorders
Keyword(s): Diagnosis, Hematological malignancy, Immune thrombocytopenia (ITP), Platelet